Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of reduced dose are alternative treatment strategi...

Full description

Bibliographic Details
Main Authors: Qing Tian, Liang-an Chen
Format: Article
Language:English
Published: Karger Publishers 2011-09-01
Series:Case Reports in Oncology
Subjects:
Online Access:http://www.karger.com/Article/FullText/332195

Similar Items